Posted by Michael Wonder on 16 May 2023
U.S. Food and Drug Administration issues complete response letter for Byondis' trastuzumab duocarmazine
15 May 2023 - Complete response letter outlines FDA's request for additional information.
Byondis today announced that the US FDA has issued a complete response letter for the biological license application for [vic-]trastuzumab duocarmazine (SYD985).
